Casirivimab
Based on 2 publication(s) in Google Scholar
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms.
For research use only. We do not sell to patients.
- Purity: 99.54%
- CAS No.: 2415933-42-3
- Molecular Weight:145.24 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Casirivimab
More
Biological Activity
Human IgG1 kappa
Virus
SARS-CoV-2
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:K18-hACE2 mice vaccinated with the SARS-CoV-2 δ or Omicron variant[2]
-
Dosage:400μg; single dose
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Decreased amount of subgenomic E RNA (sgE RNA), which reduced the viral load and improved lung pathology in δ. Weakened antiviral effectiveness in the body against Omicron.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
YP_009724390.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized SARS-CoV-2 S Protein RBD (HEK293) can bind Casirivimab. The EC50 for this effect is 1.773 ng/mL.
Chemical Information
-
CAS No. 2415933-42-3
-
Appearance Liquid
-
Molecular Weight 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Casirivimab]
-
Synonyms
REGN10933
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
bioRxiv
A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants. [Abstract]2025 Oct 20:2025.10.16.682699. PMID: 41278696
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. [Content Brief]
[2]. Lee Tatham, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024 Aug 6;12(8):e0391623. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz